Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

• Results Overview

  Upadacitinib treatment showed lasting effectiveness through 52 weeks in treating moderate-to-severe atopic dermatitis, with both 15mg and 30mg doses maintaining improvements in skin clearance and itch relief, though the 30mg dose showed slightly better results with some increased side effects.

• Study Summary

  Num Participants:

  1,609

  Study Type:

  Rct

  Control Group:

  Placebo

  Efficacy End Points Treatment:

  {'EASI-75': 82.0, 'vIGA-AD 0/1': 59.2, 'WP-NRS': 67.3}

  Efficacy End Points Control:

  {'EASI-75': 26.0, 'vIGA-AD 0/1': 11.0, 'WP-NRS': 15.0}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Acne	Low	10.0
  Herpes Zoster	Medium	3.6
  Serious Infection	High	2.2

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected